iShares Biotechnology ETF
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2.36% less ownership
Funds ownership: 70.93% [Q4 2024] → 68.57% (-2.36%) [Q1 2025]
5% less funds holding
Funds holding: 862 [Q4 2024] → 819 (-43) [Q1 2025]
13% less capital invested
Capital invested by funds: $4.59B [Q4 2024] → $3.97B (-$618M) [Q1 2025]
27% less funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 8 (-3) [Q1 2025]
36% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 76
46% less repeat investments, than reductions
Existing positions increased: 192 | Existing positions reduced: 354
54% less call options, than puts
Call options by funds: $293M | Put options by funds: $630M
Research analyst outlook
We haven’t received any recent analyst ratings for IBB.
Financial journalist opinion
Based on 7 articles about IBB published over the past 30 days
Neutral
Fox Business
2 weeks ago
Trump's deadline looms for Big Pharma companies facing new tariffs
'The Big Money Show' panel discusses President Donald Trump's pharmaceutical tariff strategy.
Neutral
Investors Business Daily
2 weeks ago
Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn
Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month, making good on months of threats.
Neutral
WSJ
2 weeks ago
Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff
A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.
Neutral
The Street
3 weeks ago
Trump threatens 50% tariffs on copper, 200% on pharmaceuticals
However, the President did not disclose when the tariffs would take effect.
Negative
Investors Business Daily
3 weeks ago
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon."
Neutral
Seeking Alpha
3 weeks ago
Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI
IBB and XBI are similar in many ways, but their relative past performance does not tell the story. IBB is more concentrated, and that is ultimately why I prefer it to XBI. Both ETFs target a similar objective, and are over-diversified. For reasons I explain here.
Positive
Seeking Alpha
3 weeks ago
5 Stocks I'm Buying As The 'Big Beautiful Bill' Pushes The Market To New Highs
The Big Beautiful Bill boosts defense, industrials, and manufacturing, but healthcare and some REITs face headwinds from Medicaid cuts and policy shifts. AI optimism and the new legislation are fueling a broad market rally, but I question if AI stocks are outpacing their earnings, signaling a potential bubble. The Magnificent 7 era is over; META, MSFT, NVDA, and AMZN are the new leaders, while AAPL, GOOG, and TSLA face unique challenges in the AI race.
Neutral
Zacks Investment Research
1 month ago
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Neutral
CNBC Television
1 month ago
Fast Money: WTI, IBB, UBER, CAT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Neutral
Zacks Investment Research
1 month ago
Should You Invest in the iShares Biotechnology ETF (IBB)?
Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
Charts implemented using Lightweight Charts™